NASDAQ
20.11.24
22:00 Uhr
0,178 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Lyra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary | 2 | Reuters | ||
| 13.11. | Lyra Therapeutics stock plunges to 52-week low of $0.21 | 4 | Investing.com | ||
| 13.11. | Lyra Therapeutics-Aktie stürzt auf 52-Wochen-Tief von 0,21 US-Dollar | 3 | Investing.com Deutsch | ||
| 13.11. | Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M | 3 | Seeking Alpha | ||
| 12.11. | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 46 | GlobeNewswire (Europe) | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| 12.11. | Lyra Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Lyra Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.10. | Lyra Therapeutics schließt Patientenrekrutierung für Phase-3-Studie zur CRS-Behandlung ab | 5 | Investing.com Deutsch | ||
| LYRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.10. | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis | 76 | GlobeNewswire (Europe) | -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 27.09. | Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings | 2 | GlobeNewswire (USA) | ||
| 26.09. | Aktie von Lyra Therapeutics stürzt auf 52-Wochen-Tief von 0,25 US-Dollar | 10 | Investing.com Deutsch | ||
| 26.09. | Lyra Therapeutics stock plunges to 52-week low of $0.25 | 3 | Investing.com | ||
| 15.08. | Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks | 4 | Seeking Alpha | ||
| 15.08. | H.C. Wainwright holds Lyra Therapeutics stock at 'Neutral,' awaiting Phase 3 results | 1 | Investing.com | ||
| 14.08. | Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 122 | GlobeNewswire (Europe) | - Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned - - In parallel... ► Artikel lesen | |
| 23.07. | Lyra Therapeutics, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 15.07. | Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1? | 7 | Insider Monkey | ||
| 20.06. | Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 3 | Benzinga.com | ||
| 18.06. | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis | 192 | GlobeNewswire (Europe) | ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 19,382 | -0,83 % | Bayer-Aktie: Kursziele fallen nach dem Absturz | Die Bayer-Aktie hat in dieser Woche nach den Quartalszahlen einen massiven Absturz erlebt. Doch mit dem Abverkauf scheint es kein Ende zu nehmen, zumal die Analysten aktuell negative Urteile über den... ► Artikel lesen | |
| PFIZER | 23,615 | -0,23 % | Kurs von Pfizer bricht ein (23,4567 €) | An der US-amerikanischen Börse fällt zur Stunde das Wertpapier von Pfizer negativ auf. Der Kurs des Anteilsscheins sackt kräftig ab. Zu den größten Verlierern des Tages am Aktienmarkt zählt gegenwärtig... ► Artikel lesen | |
| INNOCAN PHARMA | 0,148 | +6,12 % | Breaking News: InnoCan Pharma erzielt 24 Mio. USD Umsatz… | ||
| ASTRIA THERAPEUTICS | 8,950 | -1,65 % | Astria TherapeuticS GAAP EPS of -$0.42 in-line | ||
| ASSEMBLY BIOSCIENCES | 14,150 | -0,70 % | Assembly Biosciences - Herpes-Wirkstoff übertrifft Erwartungen | Mein diesjähriger Top-Favorit Assembly Biosciences (WKN: A402CB) präsentierte gestern herausragende Studiendaten seines Wirkstoffkandidaten ABI-5366 zur Behandlung von wiederkehrendem Genitalherpes.... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,190 | 0,00 % | Tonix Pharmaceuticals Holding: Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments | This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 7,890 | +3,00 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
| NEKTAR THERAPEUTICS | 0,933 | -2,25 % | Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence | - NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18,... ► Artikel lesen | |
| COMPASS PATHWAYS | 4,480 | +1,36 % | Compass Pathways plc: Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates | Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point... ► Artikel lesen | |
| ALTIMMUNE | 7,908 | +3,59 % | Altimmune, Inc: Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 | ||
| ROCKET LAB USA | 19,380 | +1,25 % | Is Rocket Lab Stock a Millionaire Maker? | ||
| CORBUS PHARMACEUTICALS | 15,100 | -1,31 % | Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 13.5% in October | ||
| OPUS GENETICS | 0,949 | +2,48 % | Foundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics | The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD)
RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal... ► Artikel lesen | |
| TALPHERA | 0,633 | -5,38 % | Talphera, Inc.: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling... ► Artikel lesen | |
| SOLIGENIX | 3,510 | 0,00 % | Soligenix, Inc.: Soligenix to Present at November 21st Virtual Investor Summit Microcap Event | PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to... ► Artikel lesen |
LYRA THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,178 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYRA THERAPEUTICS INC finden Sie auf Wallstreet Online.
